Underdosed and mislabelled: what testing actually finds
Four different things go wrong with a peptide vial. They look identical from outside the package, they need different tests to find, and they appear differently on a report.
“Is this legit” is one question to a buyer and four questions to a laboratory. The four have almost nothing in common analytically: one is answered by matching the sample against reference data for the named compound, one by quantitation against a reference standard, one by chromatographic separation, and one by an entirely different set of instruments. Ordering the wrong one produces a technically correct report that answers a question you were not asking.
Failure one: it is not the compound on the label
Substitution: a vial containing a different molecule than the one named. It ranges from a related analogue of the same class through to something unrelated, and it is not always deliberate; vials get mislabelled during filling as readily as during selling.
What finds it: Identity confirmation. The sample is compared against reference data for the compound named at scope review, here using a selection of FTIR-ATR, Raman spectroscopy, capillary electrophoresis with UV detection, and UV-Vis spectroscopy, chosen to suit the molecule. A clear mismatch against the reference is unambiguous.
What misses it: A purity test. If the vial holds one clean compound that happens to be the wrong one, purity can read beautifully. This is why identity and purity are reported together rather than purity alone.
The limit: No identity technique separates stereoisomers on its own, and all of them struggle between closely related analogues that differ by very little. Where a result looks anomalous or two candidates are close, LC-MS confirmation can be arranged at a contract laboratory and is named on the certificate where it was used.
Failure two: there is less of it than the label says
A content shortfall. The compound is correct, the material is clean, and the vial simply holds fewer milligrams than it claims. This is the failure most invisible to casual testing.
What finds it: Quantitative content testing against a calibrated reference standard, reported alongside the stated label claim. It is not run by default and is requested at scope review, subject to a suitable reference standard being obtainable for the compound.
What misses it: Purity, structurally and unavoidably. Area purity is the principal peak’s share of total detected response. Underfilling removes material from the numerator and the denominator in the same proportion, so the ratio does not move. A one-third-full vial can report 99% purity honestly.
The complication: Not every shortfall is a shortfall. Counter-ion and residual moisture are real mass in the powder that is not peptide, so a vial filled to 10 mg gross weight legitimately contains less than 10 mg of peptide base. This is why the calculation basis has to be agreed before the measurement rather than argued about after it.
Failure three: it is the right compound but not clean
Low purity. The target is present and correct, alongside a meaningful amount of something else, usually synthesis-related: truncation and deletion sequences, incompletely deprotected material, oxidation products, or degradation from poor storage.
What finds it: Reversed-phase HPLC with the resolved related substances reported individually rather than folded into a single total.
What misses it: An identity test alone. Identity evidence confirms the target is present; it does not measure how much of the sample is something else. It also misses anything the method failed to resolve; co-eluting material integrates into the principal peak and inflates the purity figure.
What it reveals: The impurity profile is often more informative than the headline percentage. A family of peaks just before the principal one has a different story behind it than a single large late-eluting peak.
Failure four: something is present that should not be
Contamination: bacterial endotoxin or elemental impurities. These are not detected by any peptide panel, at all, under any circumstances. They are separate instruments answering separate questions.
What finds it: Kinetic chromogenic LAL for endotoxin, and an atomic absorption screen for lead, arsenic, cadmium and mercury, with ICP-MS confirmation at a contract laboratory where the screen warrants it. Each reports against its own limit. Microbial enumeration, which answers a third contamination question, is not offered by this laboratory.
What misses it: Everything else. A perfect identity, purity, and content report says nothing whatsoever about contamination, and should not be read as reassurance about it.
The limit that matters most here: none of these is a sterility test. A low endotoxin figure does not establish that a container is sterile, and this laboratory does not offer sterility testing.
What a result cannot tell you
Analysis describes the state of the material that arrived. It does not attribute cause. A low content figure is consistent with a manufacturing shortfall, with degradation in storage, with heat damage in transit, and with a vial that was opened and partly used before submission. The report says what was measured; it cannot say which of those happened.
Nor does one vial speak for a lot. A result applies to the unit tested, in both directions: a good result does not certify the box it came from, and a bad one does not condemn it. Saying anything about a lot requires a sampling plan across multiple units, which is a different scope with a different price.
Choosing scope for the question you actually have
If you are checking a new supplier and do not know what you are looking for, identity and purity together is the sensible floor, because it catches the two failures most likely to be systematic. Add content whenever the label claim matters to you (and for anything sold by the milligram, it usually does). Add contaminant screening when the material’s intended handling makes it relevant, and understand that it is a genuinely separate question rather than a thoroughness upgrade.
Further reference
Sources and related guidance for this article:
- ICH Q2(R2): Validation of Analytical Procedures
Framework for evaluating analytical procedure performance; this reference does not certify CPT or an individual result.
- CPT testing methods and reporting scope
Published service scope and technique-specific reporting information.
Common questions
What is the most common problem found in peptide testing?
The failure modes are distinct and need different tests to find, so no single one is "most common" across all submissions. What is consistent is that content shortfalls are invisible to a purity panel: a vial can pass a purity test cleanly while holding well under its labelled amount, because purity is a ratio and a ratio does not move when a vial is underfilled.
If a peptide is the wrong compound, will a purity test show it?
Not reliably. A purity test reports how much of the detected signal belongs to the principal peak. If the vial contains a single clean compound that simply is not the one on the label, the purity figure can be excellent. Identity confirmation against reference data for the named compound is what catches a substitution, which is why identity and purity are reported together as one core analysis rather than separately.
Can testing tell me who is responsible for a problem?
No. Analysis describes the sample received. It cannot distinguish a manufacturing shortfall from degradation in a warehouse, from damage in transit, or from a vial that was opened before submission. A result establishes the state of the material on arrival, and nothing about how it got that way.
Does one bad result mean the whole batch is bad?
No. One vial is one vial. A result applies only to the unit tested and cannot be extended to untested units in the same lot, in either direction. Establishing anything about a lot requires a sampling plan across multiple units, which is a different scope and is quoted as one.